Cel Mol Med 23 (6), 40634075
Book a consultation today
Text us and well help you compare options at your consultation
doi: 10.1093/plphys/kiad596
Disclosures: Emmanuel Dixon: Nothing to Disclose, thierry claudel: Nothing to Disclose, Jakob-Wendelin Genger: Nothing to Disclose, Ci Zhu: Nothing to Disclose, Sarah Stadlmayr: Nothing to Disclose, Erika Paolini: Nothing to Disclose, Alexander Nardo: Nothing to Disclose, Veronika Mlitz: Nothing to Disclose, Claudia Fuchs: Nothing to Disclose, Andreas Bergthaler: Nothing to Disclose, Paola Dongiovanni: Nothing to Disclose, Wilfried Ellmeier: Nothing to Disclose, Michael Trauner: Albireo: Grant/Research Support, Alnylam: Grant/Research Support, Cymabay: Grant/Research Support, Falk: Grant/Research Support, Gilead: Grant/Research Support, Intercept: Grant/Research Support, MSD: Grant/Research Support, Takeda: Grant/Research Support, Ultragenyx: Grant/Research Support, Abbvie: Travel Grants, Falk: Travel Grants, Gilead: Travel Grants, Intercept: Travel Grants, Janssen: Travel Grants, Abbvie: Advisor, Albireo: Advisor, BiomX: Advisor, Boehringer Ingelheim: Advisor, Falk Pharma GmbH: Advisor, Genfit: Advisor, Gilead: Advisor, Hightide: Advisor, Intercept: Advisor, Ipsen: Advisor, Janssen: Advisor, MSD: Advisor, Novartis: Advisor, Phenex: Advisor, Pliant: Advisor, Regulus: Advisor, Siemens: Advisor, Shire: Advisor, BMS: Speaking and Teaching, Falk: Speaking and Teaching, Gilead: Speaking and Teaching, Intercept: Speaking and Teaching, Ipsen: Speaking and Teaching, Madrigal: Speaking and Teaching, MSD: Speaking and Teaching, Medical Universities of Graz and Vienna: Co.Inventor of patents for medical use of norUDCA filed by 2630 S-ADENOSYLMETHIONINE PROTECTS AGAINST FOLFOX-INDUCED LIVER INJURY BY INHIBITING PLASMINOGEN ACTIVATOR INHIBITOR-1 IN MICE Alexandra Gangi 1 Youngyi Lim 1 Tony Li 1 Andrea Floris 1 Swati Chandla 1 Maria Lauda Tomasi 1 Shelly Lu 1 , 1 Cedars Sinai Medical Center Background: Folinic acid, 5-Fluorouracil and Oxaliplatin (FOLFOX), a commonly used chemotherapeutic regimen in patients with colorectal liver metastasis (CRLM), can cause liver injury such as sinusoidal obstruction syndrome (SOS) that limits further treatment
Thalassemia and venous thromboembolism
